Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Oxidoreductases
Reexamination Certificate
2005-11-22
2005-11-22
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Oxidoreductases
C424S450000, C424S455000, C514S006900
Reexamination Certificate
active
06967020
ABSTRACT:
An oxygen carrier system includes an artificial oxygen carrier including hemoglobin vesicles encapsulating hemoglobin and an intermediate electron mediator having a standard electrode potential of 0.05 V to 0.56 V (vs. the standard hydrogen electrode) in the vesicles, and a reducing agent which is added to an external aqueous phase of the hemoglobin vesicle to reduce methemoglobin when the hemoglobin encapsulated in the hemoglobin vesicle is oxidized to the methemoglobin. The reducing agent has, as an active component, at least one compound selected from the group consisting of a thiol compound and a reducing sugar.
REFERENCES:
patent: 2002/0095108 (2002-07-01), Tsuchida et al.
patent: 04-059735 (1992-02-01), None
patent: WO 01/95930 (2001-12-01), None
Takeoka, S., et al. 1997 Methemoglobin Formation in Hemoglobin Vesicles and Reduction by Encapsulated Thiols. Bioconjugate Chem. 8: 539-544.
Ljubomir Djordjevich, et al., “Lipid Encapsulated Hemoglobin as a Synthetic Erythrocyte”, Federation Proceedings, vol. 36, No. 3, 1977, p. 567.
S. Takeoka, et al., “Evaluation of the Oxygen Transporting Capability of Hemoglobin Vesicles”, Blood Substitutes, Present and Future Perspectives, 1998, pp. 171-184.
Hiromi Sakai, et al., “Suppression of Methemoglobin Formation by Glutathione in a Concentrated Hemoglobin Solution and in a Hemoglobin-Vesicle”, Bull. Chem. Soc. Jpn., vol. 67, No. 4, 1994, pp. 1120-1125.
Shinji Takeoka, et al., “Methemoglobin Formation in Hemoglobin Vesicles and Reduction by Encapsulated Thiols”, Bioconjugate Chem., vol. 8, No. 4, 1997, pp. 539-544.
Hiromi Sakai, et al., “Photoreduction of Methemoglobin by Irradiation in the Near-Ultraviolet Region”, Biochemistry, vol. 39, No. 47, 2000, pp. 14595-14602.
Hiromi Sakai, et al., “Physical Properties of Hemoglobin Vesicles as Red Cell Substitutes”, Biotechnol. Prog., vol. 12, No. 1, 1996, pp. 119-125.
Hiromi Sakai, et al., “Surface Modification of Hemoglobin Vesicles with Poly(ethylene glycol) and Effects on Aggregation, Viscosity, and Blood Flow during 90% Exchange Transfusion in Anesthetized Rats”, Bioconjugate Chem., vol. 8, No. 1, 1997, pp. 23-30.
Teraoka et al, Polymer Preprints, Japan, vol. 51, No. 5, 2002, p. 956.
Takeoka et al, Bull. Chem. Soc. Jpn., vol. 70, 1997, pp. 1171-1178.
Atoji Tomoyasu
Takeoka Shinji
Teramura Yuji
Tsuchida Eishun
Carlson Karen Cochrane
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Oxygenix Co., Ltd
Tsay Marsha
LandOfFree
Oxygen carrier system, artificial oxygen carrier, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxygen carrier system, artificial oxygen carrier, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxygen carrier system, artificial oxygen carrier, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3511142